Digitisation | April 19, 2024
Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome
Around 7% of the Indian population suffers from IBS
Around 7% of the Indian population suffers from IBS
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Partnership with Modality, award-winning GP super partnership
Subscribe To Our Newsletter & Stay Updated
